Expand Prescription Drug Donation Program
SB 122 expands New Mexico’s prescription drug donation program by broadening who may donate unused prescription drugs and who may receive, inspect, store, and redistribute them. Under the bill, any person, including out-of-state donors, may donate unexpired unused prescription drugs to eligible recipients, and eligible recipients may include licensed pharmacies, licensed health care facilities, and licensed prescribers. The bill also directs the board to adopt rules for handling donated drugs, including procedures for refrigerated drugs, standards for inspection and storage, and requirements to ensure that only safe, unadulterated, tamper-evident drugs are redistributed.
The bill is designed to increase access to medications by allowing donated drugs to be redistributed to patients when the drugs will not expire before they can be fully used. It also authorizes in-state and out-of-state pharmacies experienced in managing donated drugs to participate, including through mail-order pharmacy distribution. The program excludes controlled substances and requires compliance with applicable federal and state laws governing drug handling and redistribution.
SB 122 amends Section 26-1-3.2 NMSA 1978 to expand the state’s prescription drug donation framework and to give the board additional rulemaking authority over collection, inspection, labeling, storage, and redistribution of donated medications. It also creates or clarifies liability protections for donors, recipients, and others who exercise reasonable care, while preserving the liability of manufacturers, distributors, and dispensers except as otherwise provided. The bill further allows eligible recipients to charge a handling fee limited to reasonable costs and requires the board to maintain a public list of eligible recipients.
The bill appears to have broad bipartisan support and was approved overwhelmingly in both chambers, passing the Senate 40-0 and the House 55-6. That voting pattern suggests general agreement that expanding the donation program is a practical way to reduce waste and improve access to prescription drugs. No committee transcript was provided, so the available record shows strong overall support with limited visible opposition.
The main policy concerns likely center on patient safety, drug integrity, and liability. The bill addresses these by requiring inspection, tamper-evident packaging, storage compliance, and board-promulgated standards, and by excluding controlled substances. Another possible point of contention is the scope of immunity for those handling donated drugs, though the bill preserves manufacturer liability rules and limits immunity to those exercising reasonable care. The narrow House opposition in the final vote suggests some lawmakers may have had reservations about safety, regulatory burden, or legal exposure, but the record does not identify specific arguments.